The introduction of novel prognostic factors such as minimal residual disease (MRD) and genomic profiling has led to the reevaluation of the role of cytogenetics and other conventional factors in risk stratification for acute lymphoblastic leukemia (ALL). METHODS: This study assessed the impact of baseline cytogenetics on the outcomes of 428 adult patients with Philadelphia chromosome-negative ALL who were receiving frontline chemotherapy. Three hundred thirty patients (77%) were treated with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone-based regimens, and 98 (23%) were treated with the augmented Berlin-Frankfurt-Munster regimen. RESULTS: The median age was 40 years (range, 13-86 years). One hundred eighty-six patients (43%) had diploid cytogenetics, 32 (7%) had complex cytogenetics (defined as 5 chromosomal abnormalities), 27 (6%) had low hypodiploidy/near-triploidy (Ho-Tr), 24 (6%) had high hyperdiploidy, and 24 (6%) had a mixed-lineage leukemia (MLL) rearrangement. Patients with an MLL rearrangement, Ho-Tr, or a complex karyotype had significantly worse relapse-free survival (RFS) and overall survival (OS) than the diploid group. According to a multivariate analysis including all the baseline characteristics and MRD status, Ho-Tr and a complex karyotype were independent predictive factors for worse RFS and OS. Furthermore, survival among all cytogenetic groups was similar, regardless of the treatment received. CONCLUSIONS: A complex karyotype and Ho-Tr are adverse prognostic factors for adults with ALL independently of the MRD status. These findings suggest that pretreatment cytogenetics remain a valuable prognostic tool in this population. Cancer 2017;123:459-67.
INTRODUCTION
Acute lymphoblastic leukemia (ALL) is a genetically and clinically heterogeneous disease. 1 Despite the high response rate of ALL with standard multiagent chemotherapy, the majority of patients still relapse. 2, 3 The treatment arsenal for ALL has recently expanded with the development of novel monoclonal antibodies such as inotuzumab ozogamicin and blinatumomab, which are able to achieve profound responses even in patients with heavily pretreated relapsed or refractory disease, 4, 5 and there is significant interest in moving these agents to the frontline setting. The early identification of patients at high risk for relapse is important for the development of comprehensive strategies that use all available treatment modalities to prevent relapse and improve outcomes in these patients.
The success of multiagent combination chemotherapy regimens for the treatment of pediatric and adult ALL is likely due to their ability to overcome the heterogeneity of this disease. ALL is commonly associated with various structural chromosomal abnormalities and changes in the total number of chromosomes (or ploidy), which represent its underlying genetic heterogeneity. There have been conflicting reports on the prognostic impact of these chromosomal changes in adult ALL. Although Moorman et al 6, 7 reported that a complex karyotype, low hypodiploidy, and near-triploidy are independent adverse prognostic factors in adult ALL, recent reports on patients treated with pediatric-inspired regimens have failed to confirm these findings. 8, 9 Conclusive answers to the clinical impact of ploidy in adult ALL have been difficult to obtain because of the relatively low frequency of each of these cytogenetic subgroups. Furthermore, in recent years, minimal residual disease (MRD) assessment has emerged as a strong predictor for relapse and survival in ALL. 10, 11 To this end, we sought to determine the prognostic impact of complex karyotype and ploidy cytogenetic subgroups in adult patients with Philadelphia chromosome (Ph)-negative ALL.
MATERIALS AND METHODS

Patients
We conducted a retrospective analysis that included patients enrolled in clinical trials investigating frontline chemotherapy for ALL (NCT00671658, NCT00866749, NCT00501826, NCT01363128, and NCT01371630). Between May 2000 and March 2015, 428 adult patients with previously untreated Ph-negative ALL received frontline chemotherapy at our institution with either hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD) or augmented BerlinFrankfurt-Munster (BFM)-based chemotherapy and had an adequate pretreatment cytogenetic assessment. All patients signed an informed consent form for clinical trial participation, and all trials were approved by the institutional review board of The University of Texas MD Anderson Cancer Center (MDACC).
Treatments
Three hundred thirty patients (77%) were treated with hyper-CVAD-based regimens, and 98 (23%) were treated with the augmented BFM regimen. The augmented BFM regimen was administered only to patients less than 40 years old. The details of these regimens have been published elsewhere. 12, 13 All patients with CD20-positive ALL treated with hyper-CVAD-based regimens received anti-CD20 monoclonal antibodies.
Response and Outcome Definitions
Complete remission (CR) was defined as the presence of <5% blasts in the bone marrow with >1 3 10 9 /L neutrophils and >100 3 10 9 /L platelets in the peripheral blood with no evidence of extramedullary disease. Complete remission with an inadequate platelet response (CRp) was defined as meeting the criteria for CR but with a platelet count 100 3 10 9 /L. Relapse was defined by the recurrence of 5% blasts in a bone marrow aspirate or by the presence of extramedullary disease. Overall survival (OS) was calculated from the time of treatment initiation to death from any cause. Relapse-free survival (RFS) was measured from the date of CR/CRp to relapse or death from any cause.
Cytogenetic Analysis
Bone marrow specimens for cytogenetic assessment were obtained before the initiation of treatment in all patients. Cytogenetic studies were performed with the standard Gbanding technique at MDACC's cytogenetic laboratory. Karyotypes were interpreted with the International System for Cytogenetic Nomenclature criteria by expert pathologists at our institution. 14 Designation as a diploid karyotype required a complete analysis of at least 10 metaphases with good-quality banding. Patients were classified according to the Medical Research Council (MRC) United Kingdom Acute Lymphoblastic Leukemia (UKALL)XII/Eastern Cooperative Oncology Group (ECOG) E2993 karyotypic categories. 6 Low hypodiploidy, defined as the presence of 30 to 39 chromosomes, and near-triploidy, defined as 60 to 78 chromosomes, were combined for the purposes of analysis as previously described. 15 No patients with near-haploidy (<30 chromosomes) were identified in this cohort. High hyperdiploidy (HeH) was defined as the presence of 51 to 65 chromosomes, and tetraploidy was defined as 80 chromosomes. The definition of a complex karyotype has been reported in the literature as either 3 or 5 chromosomal abnormalities. 6, 16 Thus, analyses of both groups were performed in comparison with the diploid group to determine the most prognostic definition of a complex karyotype; those abnormalities included any abnormality except for established recurrent translocations such as t(4;11)(q21;q23), other mixed-lineage leukemia (MLL)/ 11q23 translocations, and t(1;19)(q21; p13.3). All other nondiploid karyotypes were further categorized according to the structural changes, which included chromosomal translocations, gains, and losses. The categorization of patients into all the aforementioned subgroups was performed by 2 independent observers, including an expert hematopathologist.
MRD Assessment
Multiparameter flow cytometry (MFC) was used as previously described for MRD assessment. 10 The MRD assessment was performed at the time of CR. Initially, a 15-marker, 4-color panel was used; later, a 6-color panel was used. An aberrant population was defined as a cluster of at least 20 cells, and an MRD-positive value was assigned when there was expression of 2 or more aberrant antigens. The sensitivity of this MRD assay was 0.01%.
Statistical Analysis
The relations between cytogenetic subgroups and categorical variables were analyzed with the Fisher exact test, and the Kruskal-Wallis test was used to compare continuous variables. RFS and OS were calculated with Kaplan-Meier estimates, and survival estimates were compared with the log-rank test. The multivariate analysis was performed with the Cox proportional hazards model for the risk of relapse or death. The cytogenetic group, T-cell lineage status, sex, performance status, chemotherapy regimen, and MRD status at CR were included as categorical variables, whereas age, blood tests (including the white blood cell count [WBC]), and blast percentages were treated as continuous variables. Models were fitted with stepwise forward selection; variables were added to the model if P was .05 in the univariate analysis. Computations were performed with the SAS (version 9.4), TIBCO Spotfire S 1 (version 8.2), and GraphPad Prism (version 6.07) statistical programs.
RESULTS
Description of the Chromosomal Abnormalities
Among the 428 evaluable patients, 186 patients (43%) had a diploid karyotype. Chromosomal abnormalities forming a complex karyotype did not include known recurrent translocations in ALL, as previously described in the literature. 6 Twenty-four patients (6%) had 3 or 4 chromosomal abnormalities, 32 (7%) had 5 or more chromosomal abnormalities, 27 patients (6%) had low hypodiploidy/near-triploidy (Ho-Tr), 24 (6%) had HeH, and only 6 (1%) had tetraploidy. Twenty-four patients (6%) had an MLL rearrangement. Forty-nine patients (11%) had previously described recurrent chromosomal abnormalities; most of them had concurrent multiple abnormalities (Fig. 1 ). Other chromosomal abnormalities not previously described as recurrent were present in 56 cases (13%).
Chromosomes were differentially involved among various ploidy groups and among patients with complex karyotypes. Cytogenetic alterations in chromosomes 3, 7, 13, and 16 were most commonly present in the Ho-Tr group (82%, 75%, 72%, and 72%, respectively). In the HeH group, the commonly altered chromosomes were chromosome 21 (88% of patients), chromosome 14 (80% of patients), and chromosome 4 (68% of patients). Chromosomes 8, 5, and 7 were most commonly altered in the complex karyotype group (46%, 46%, and 43% of patients, respectively). The median number of metaphases involved in patients with Ho-Tr, HeH, and a complex karyotype was 8, 11, and 11 of 20 metaphases, respectively.
Clinical and Hematologic Presentation
Baseline characteristics are summarized in Table 1 . The median age of the cohort was 40 years (range, 13-86 years). Patients with Ho-Tr (median age, 62 years; range, 18-78 years) were significantly older than those with a diploid karyotype (median age, 39 years; range, 15-84 years; P < .001). The Ho-Tr group also had a lower platelet count (median count, 25 3 10 9 /L) than the diploid group (median count, 65 3 10 9 /L; P < .001). All patients in the Ho-Tr, HeH, and MLL subgroups exclusively had a B-cell phenotype. Patients with a tetraploidy karyotype were older than diploid patients (P < .001). Compared with diploid patients, those with MLL had higher WBCs and bone marrow blast percentages (P 5 .01).
Treatment Response
Overall, 389 patients (90%) achieved CR, and 11 (3%) achieved CRp; 12 (3%) had resistant disease, and 13 (3%) died before the first response assessment (Table 1) . Patients in the different cytogenetic subgroups had similar responses. Among the 11 patients with resistant disease, 3 patients had a diploid karyotype, 2 patients had HeH, 2 patients had a complex karyotype, and 4 had other chromosomal abnormalities.
An MRD assessment by MFC was performed for 285 patients (73% of the patients with CR/CRp). One hundred seventy-eight patients (62%) were MRD-negative at CR, 96 (34%) were MRD-positive, and 11 (4%) had an indeterminate MRD assessment (Table 1) . There was no difference in the rates of MRD negativity among the cytogenetic subgroups analyzed (P 5 .28).
Survival by Cytogenetics and MRD Assessment
With a median follow-up time for survivors of 58 months, the 5-year RFS and OS rates for the entire cohort were 36% and 47%, respectively. The OS of patients with 3 or 4 chromosomal abnormalities (5-year OS rate, 53%; 95% confidence interval [CI], 45%-62%) was similar to the OS of patients with a diploid karyotype (5-year OS rate, 51%; 95% CI, 27%-63%; P 5 .51). In contrast, the 5-year OS rate of patients with 5 or more chromosomal abnormalities was 28% (95% CI, 12%-46%), which was significantly worse than the rate of patients with a diploid karyotype (P < .001; Fig. 2) . Thus, for the purpose of further analyses, a complex karyotype was defined as the presence of 5 or more chromosomal abnormalities. Furthermore, patients with other chromosomal abnormalities (1 or 2 abnormalities) who were not previously described as recurrent had outcomes similar to those of patients with diploid cytogenetics (P 5 .55).
Patient with Ho-Tr, a complex karyotype, or MLL had worse RFS and OS than the diploid group (Table 2 and Fig. 3 ). The 5-year RFS rates for the Ho-Tr, complex karyotype, and MLL translocation groups were 24%, 12%, and 18%, respectively (Fig. 3A) . Similarly, the 5-year OS rates were 35%, 29%, and 25%, respectively (Fig. 3B) . Patients with HeH had better outcomes with 5-year RFS and OS rates of 77% and 71%, respectively (the difference in OS did not reach statistical significance; Table 2 and Fig. 3) . Thus, patients with an MLL rearrangement, Ho-Tr, or a complex karyotype were found to have poor-risk disease. Subsequently, the survival impact of poor-risk cytogenetics was assessed according to the chemotherapy regimen received. Patients with poor-risk cytogenetics who were treated with either hyper-CVAD or augmented BFM regimens had similarly worse survival in comparison with the diploid group with median survival times of 1.5 and 1.6 years, respectively (log-rank P 5 .8).
We subsequently assessed the impact of the MRD status on the outcomes of patients in the different cytogenetic subgroups. The median OS was 1.8 years for patients with a positive MRD status and poor-risk cytogenetics and 3.7 years for patients with a positive MRD status and diploid cytogenetics; the hazard ratio (HR) was 2.5 (95% CI, 1.4-7.2; P 5 .005; Fig. 4A ). The prognostic impact of poor-risk cytogenetics was still significant in patients who achieved MRD negativity (Fig. 4B) . The median OS was 3.4 years for patients who achieved MRD negativity but had poor-risk cytogenetics and 9.7 years for patients with MRD negativity and diploid cytogenetics; the HR was 2.0 (95% CI, 1.1-4.7; P 5 .01). Thus, patients with poor-risk cytogenetics and a positive MRD status at CR had worse survival. A total of 30 patients (7%) underwent allogeneic stem cell transplantation (ASCT) during their first CR; 15 (50%) had Ho-Tr, MLL, or complex cytogenetics. Eighteen patients relapsed, and 16 died. At the last follow-up, 14 patients (47%) remained alive; 4 of these patients had poor-risk cytogenetics.
Multivariate Analysis for Survival
The prognostic impact of the cytogenetic subgroups was evaluated in a multivariate analysis for RFS and OS (Table 3). According to the multivariate analysis, an older age, a higher WBC count, thrombocytopenia, Ho-Tr, complex cytogenetics, and a positive MRD status at CR were independent predictive factors of poor RFS. An older age, a higher WBC count, Ho-Tr, complex cytogenetics, and a positive MRD status at CR were independent predictive factors of poor OS as well. The risk of death for patients with a complex karyotype was significantly higher than the risk for those with a diploid karyotype; this was independent of all other factors analyzed, including the MRD status, with an HR of 2.42 (95% CI, 1.26-4.66; P 5 .01). Similarly, the risk of death for patients with Ho-Tr was higher than that for diploid patients with an HR of 3.15 (95% CI, 1.40-7.09; P 5 .01). Despite worse survival according to the univariate analysis, an MLL rearrangement was not independently predictive of either RFS or OS.
DISCUSSION
In this study, we evaluated the impact of cytogenetic abnormalities in adult patients with Ph-negative ALL. We found that cytogenetic analysis adds independent prognostic information. A multivariate analysis confirmed the independent prognostic impact of a complex karyotype and Ho-Tr even when the MRD status was included in the analysis. In contrast, HeH was associated with improved RFS and a trend toward improved OS, as has been described for pediatric ALL. 17 As previously described, patients with an MLL rearrangement had a higher WBC, and this perhaps explains why MLL was not identified as an independent factor in the multivariate analysis. 6 Our findings further support the definition of a complex karyotype in ALL as 5 chromosomal abnormalities. Reports have previously described a complex karyotype as either 3 16 or 5 abnormalities. 6 We found that the clinical outcomes of these 2 groups were drastically different. The survival of patients with 3 abnormalities was similar to that of patients with a diploid karyotype; this contrasted with significantly worse survival for patients with 5 abnormalities. Furthermore, the adverse outcomes of poor-risk cytogenetics (defined as the presence of a complex karyotype, Ho-Tr, or MLL rearrangement) were similar for both the hyper-CVAD cohort and the augmented BFM cohort.
There have been previous studies attempting to determine the impact of cytogenetics, with some conflicting results; the largest was the MRC UKALLXII/ECOG E2993 study. 6, 7, 9, 18 Moorman at al identified in that study t(8;14)(q24.1;q32), Ho-Tr, and a complex karyotype as cytogenetic factors independently predictive of decreased RFS and OS. 6 The independent prognostic value of cytogenetics was also confirmed in a study by the Southwest Oncology Group. 18 However, with the emergence of MRD as a strong prognostic marker and with the identification of molecular markers such as an IKZF1 deletion and a NOTCH mutation, Beldjord et al 9 from the Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) reassessed conventional risk factors, including cytogenetics. The GRAALL study confirmed the strong predictive value of MRD and found that an MLL rearrangement is the only cytogenetic abnormality carrying prognostic significance. The differences between our findings and the French findings may be related to several factors. Patients in our cohort were older with a median age of 40 years (range, 13-86 years), whereas the median was 31 years (range, 15-60 years) in the GRAALL cohort. The age difference could possibly explain the higher incidence of Ho-Tr (11/423 in the GRAALL cohort vs 27/ 428 in the MDACC cohort) because Ho-Tr is more common in older patients. 7 Other important factors are the inclusion of molecular data in the GRAALL study and the different methods by which MRD was assessed, which could have led to different results (polymerase chain reaction vs MFC). Finally, only 7% of our patients received ASCT during CR1, whereas 37% did in the French series. As such, those factors could have led to the different conclusions.
Numerous studies have underscored the importance of MRD as a biomarker, and this has led to the reevaluation of historically prognostic pretreatment characteristics in ALL. 10, 11, 19, 20 There is no consensus on the optimal method for measuring MRD in ALL (eg, MFC, polymerase chain reaction, or next-generation sequencing). [21] [22] [23] Because of the lack of standardization for MRD detection methods, it is difficult to compare MRD assessment across different laboratories and studies. Furthermore, it is difficult sometimes to have a reliable and reproducible MRD assessment by MFC because some expertise is needed, especially in poor-resource settings. Cytogenetic analysis has been performed for years, and methods of measurement and interpretation have been standardized; this offers easier prognostication for ALL. Having both the MRD status and the cytogenetics would allow better risk stratification. Our study suggests that even if patients achieve an MRD-negative status, their outcome will be worse if they have poor-risk cytogenetics as defined by an MLL rearrangement, Ho-Tr, or a complex karyotype. In contrast, patients with diploid cytogenetics and a negative MRD status had a better outcome. Interestingly, patients with an MLL rearrangement, Ho-Tr, or a complex karyotype had MRD responses similar to those of patients with diploid cytogenetics. This may indicate the presence of residual clones with those abnormalities at levels below MRD detection, which are capable of leukemogenesis and thus relapse. In pediatric ALL, low hypodiploidy (32-39 chromosomes) has been most commonly associated with mutations in TP53, whereas near-haploidy (24-31 chromosomes) has been associated with alterations in tyrosine kinase and Ras signaling. 24 It is possible that similar associations could be found in adult ALL that could explain the higher rate of treatment failure associated with some of the cytogenetic abnormalities. Ongoing molecular profiling in our cohort of patients may help us to understand the mechanisms of resistance in patients with poor-risk cytogenetics and thus potentially identify new mutations amenable for targeting in the future.
Our study could not assess whether ASCT can improve the prognosis of patients with poor-risk Abbreviations: CI, confidence interval; Ho-Tr, low hypodiploidy/near-triploidy; MRD, minimal residual disease.
The white blood cell count and the platelet count were analyzed as the logarithm of the white blood cell count and the logarithm of the platelet count, respectively. Decreased performance status was defined as an Eastern Cooperative Oncology Group performance status 2. All cytogenetic subgroups were compared with the diploid subgroup.
cytogenetics. This was related to the relatively low frequencies of these abnormalities and the relatively low rate of transplantation during first remission (only 7%). The smaller number of patients who underwent ASCT during first remission prohibited a meaningful analysis of the interaction between cytogenetic abnormalities and ASCT. Larger studies might be needed to address this point.
In conclusion, the presence of a complex karyotype (defined as 5 chromosomal abnormalities) or Ho-Tr in adult ALL is independently predictive of RFS and OS even when MRD information is available. Results from this study could be used for risk stratification of adult ALL and allow the development of comprehensive strategies aimed at improving the outcomes of patients with a high risk of relapse. Further studies are needed to identify the mechanisms of the genomic instability in ALL and the genomic drivers associated with those cytogenetic groups that could affect prognosis.
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